24
Participants
Start Date
December 20, 2024
Primary Completion Date
May 7, 2026
Study Completion Date
May 7, 2026
M9140
M9140 will be administered every 3 weeks until progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study. There will be 2 dose levels, if the low dose level is tolerated, then M9140 will be escalated to the high dose level.
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou
RECRUITING
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou
Merck KGaA, Darmstadt, Germany
INDUSTRY
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY